Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Cabometyx® (cabozantinib) – Expanded indication
December 19, 2017 – Exelixis announced the FDA approval of Cabometyx (cabozantinib) for the treatment of patients with advanced renal cell carcinoma (RCC).
